SCHEMBL17455967

SCHEMBL17455967

c1cncc(CN2CCC(Oc3ccccc3-c3ccncc3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 2/20 0.51
▸ CHRNB2 P17787 1/20 0.50
▸ CHRNA4 P43681 1/20 0.50
▸ DRD2 P14416 1/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ SCN8A Q9UQD0 1/20 0.46
▸ TRPV6 Q9H1D0 2/20 0.46
▸ SIGMAR1 Q99720 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CHRM2 P08172 1/20 0.43
▸ CHRM3 P20309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455938 0.90 SMN1; SMN2 (0.57) SCN9ASMN1; SMN2SIGMAR1
SCHEMBL17456050 0.86 SCN9A (0.49) SCN9ACHRNB2CHRNA4DRD2DRD4
SCHEMBL17456058 0.83 SCN9A (0.49) SCN9ADRD2DRD4DRD3SMN1; SMN2
SCHEMBL17456016 0.82 HRH1 (0.43) DRD2SMN1; SMN2SIGMAR1LMNA
SCHEMBL17455985 0.81 SMN1; SMN2 (0.50) SCN9ASMN1; SMN2SCN8AALDH1A1
SCHEMBL8395893 0.80 TRPV6 (0.61) SCN9ACHRNB2CHRNA4SMN1; SMN2TRPV6
SCHEMBL17455950 0.80 CHRM3 (0.49) SMN1; SMN2LMNAKDM4EALDH1A1TDP1
SCHEMBL17455983 0.80 ALDH1A1 (0.50) SCN9ADRD4SMN1; SMN2SCN8ASIGMAR1
SCHEMBL17455994 0.80 CYP11B1 (0.55) SCN9ADRD2SMN1; SMN2SCN8ASIGMAR1
SCHEMBL17455968 0.79 SMN1; SMN2 (0.53) SCN9ADRD2DRD4DRD3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 SCN9A 565/4885CHRNB2 444/4885CHRNA4 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback